Long-cycle treatment in oral contraception;Langzyklus bei ovulationshemmern

Therapeutische Umschau

Volumn 66, Issue 2, 2009, Pages 101-108

  Kuhl, Herbert ^a   Birkhäuser, Martin ^b   Mueck, Alfred ^c   Neulen, Joseph ^d   Thaler, Christian ^e   Kiesel, Ludwig ^f   Braendle, Wilhelm ^g  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f Departement für Gynäkologie und Geburtshilfe   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIESTROGEN; AROMATASE INHIBITOR; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CYPROTERONE ACETATE; CYTOCHROME P450; DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; GONADORELIN AGONIST; GRISEOFULVIN; ISOTRETINOIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TESTOSTERONE;

AMENORRHEA; ARTERY DISEASE; BLEEDING; BLEEDING TENDENCY; BREAST CARCINOMA; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG INDUCED CANCER; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; ENDOMETRIOSIS; ESTROGEN DEFICIENCY; FEMALE FERTILITY; HEALTH SURVEY; HORMONAL CONTRACEPTION; HUMAN; HYGIENE; HYPERMENORRHEA; LIPID METABOLISM; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; MENTAL HEALTH; MIGRAINE; ORAL CONTRACEPTION; OVARY CYCLE; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PREMENSTRUAL SYNDROME; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; TREATMENT DURATION; UTERUS MYOMA; VAGINA RING; VASCULAR DISEASE; WITHDRAWAL BLEEDING;

CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; HEMORRHAGIC DISORDERS; HUMANS; LEIOMYOMA; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; METABOLIC CLEARANCE RATE; OVULATION; POLYCYSTIC OVARY SYNDROME; PREMENSTRUAL SYNDROME; UTERINE NEOPLASMS;

EID: 59849087153     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-930.66.2.101     Document Type: Review

References (33)

1. Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception - an international study on acceptability. Contraception 2003; 67: 1-8.
2. Coutinho EM, Segal SJ. Is menstruation obsolete? Oxford University Press 1999.
3. Shakespeare J, Neve E, Hodder E. Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000; 320: 291.
4. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59: 357-62.
5. Rutter W, Knight C, Vizzard J, et al. Women's attitude to withdrawal bleeding and their knowledge and beliefs about the oral contraceptive pills. Med J Aust 1988; 149: 417-9.
6. Miller L, Notter KM. Menstrual reduction with extended use of combined oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98: 771-8.
7. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regiemen to delay menses and reduce hormone withdrawal symptoms. Am J obstet Gynecol 2002; 186(6): 1142-9.
8. Sulak P, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261-6.
9. Wiegratz I, Hommel HH, Zimmermann T, et al. Attitudes of German women and gynecologists towards long-cycle treament with oral contraceptives. Contraception 2004; 69: 37-42.
10. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54: 71-7.
11. Sulak PJ, Cresman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179-83.
12. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 2004; 64: 2447-62.
13. Wiegratz I, Kissler S, Kuhl H, Kaufmann M. Extended and continuous use of hormonal contraceptives to reduce menstruation. Women's Health 2006; 2: 705-16.
14. Cachrimanidou AC, Hellberg D, Nilsson S, et al. Hemostasis profile and lipid metabolism with long interval use of a desogestrel-containing oral contraceptive.
15. Back DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990; 18: 472.
16. Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am. J. Obstet Gynecol.1999; 180: S276-S279.
17. Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B, Bulun SE. Deficient 17β-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metablize 17β-estradiol. J Clin Endocrinol Metab 1998; 83: 4474-80.
18. Brosens IA, Pijnenborg R. Comparative study of the estrogenic effect of ethinylestradiol and mestranol on the endometrium. Contraception 1976; 14: 679-85.
19. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52-61.
20. Kwiecin M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003; 67: 9-13.
21. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70: 432-9.
22. Bottini E, Pareti FI, Mari D, Mannucci PM, Muggiasca ML, Conti M. Prevention of hemoperitoneum during ovulation with oral contraceptives in women with type III of Willebrand disease and afibrinogenemia. Case reports. Haematologica 1991; 76: 431.
23. Ruchhoft E, Elkind-Hirsch KE, Malinak R. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist. Fertil Steril 1996; 66: 54-60.
24. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive: the Seasonale-301 Study Group. Contraception 2003; 68: 89-96.
25. Miller et al., Poster presentation ACOG 5/2005.
26. Miller L, Notter KM. Menstrual reduction with extended use of combined oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98: 771-8.
27. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. American College of Obstetricians and Gynecologists 2003: Vol 101; No 4.: 653-61.
28. Foidart J, Sulak P. The use of an oral contraceptive containing ethinyestradiol and drospirenone in an extended regimen over 126 days. Contraception 2006; 73: 34-40.
29. Coutinho EM, O'Dwyer E, Barbosa IC, et al. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route. Contraception 1995; 51: 355-8.
30. The European Medicines Agency (Committee for Medicinal Products for Human Use [CHMP]). Note for guidance on clinical investigation of steroid contraceptives in women [draft]. London: EMEA, 2004 Jun 23.
31. Edelman A, Gallo M, Jensen J, Nichols M, Schulz K, Gimes D. Continous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rec 2005: Jul 20; 3: CD004695.
32. Breckwoldt M. Das Prämenstruelle Syndrom. In: Sexualhormone und Psyche (Hrsg. Kuhl H), Thieme Stuttgart 2002: 18-21.
33. Grady-Weliky TA. Premenstrual dysphoric disorder. N Engl J Med 2003; 348: 433-8.